Compare CARS & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CARS | PHVS |
|---|---|---|
| Founded | 1998 | 2015 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Motor Vehicles | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 476.1M | 1.8B |
| IPO Year | 2017 | 2020 |
| Metric | CARS | PHVS |
|---|---|---|
| Price | $10.05 | $29.28 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 11 |
| Target Price | $16.00 | ★ $41.82 |
| AVG Volume (30 Days) | ★ 809.0K | 393.0K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $723,239,000.00 | N/A |
| Revenue This Year | $3.03 | N/A |
| Revenue Next Year | $2.57 | N/A |
| P/E Ratio | $125.44 | ★ N/A |
| Revenue Growth | ★ 0.57 | N/A |
| 52 Week Low | $7.40 | $15.93 |
| 52 Week High | $13.97 | $33.33 |
| Indicator | CARS | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 47.07 | 49.32 |
| Support Level | $7.64 | $24.73 |
| Resistance Level | $11.53 | $31.14 |
| Average True Range (ATR) | 0.48 | 1.55 |
| MACD | -0.16 | -0.17 |
| Stochastic Oscillator | 20.41 | 22.20 |
Cars.com Inc is an audience-powered and data-driven technology platform that simplifies buying and selling cars. The flagship Cars.com marketplace connects consumers to dealerships across the U.S., powering the car-buying experience with artificial intelligence (AI) shopping tools, vehicle reviews and content. Its ecosystem of products enables dealers and OEMs to sell more cars by leveraging the marketplace, dealer websites, trade and appraisal tools and proprietary in-market media solutions. The platform provides shoppers with data, resources and digital tools to make informed buying decisions and connect with automotive retailers. The Company also provides dealerships and OEMs with solutions and data-driven intelligence to reach and influence its 26 million monthly shoppers.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.